JP2024537839A - アキシチニブのプロドラッグ - Google Patents

アキシチニブのプロドラッグ Download PDF

Info

Publication number
JP2024537839A
JP2024537839A JP2024519989A JP2024519989A JP2024537839A JP 2024537839 A JP2024537839 A JP 2024537839A JP 2024519989 A JP2024519989 A JP 2024519989A JP 2024519989 A JP2024519989 A JP 2024519989A JP 2024537839 A JP2024537839 A JP 2024537839A
Authority
JP
Japan
Prior art keywords
compound
certain embodiments
pharmaceutical composition
ch2oco
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537839A5 (enExample
Inventor
ジャレット，ピーター
エル－ハイエク，ラミ
Original Assignee
オキュラ セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オキュラ セラピューティクス，インコーポレイテッド filed Critical オキュラ セラピューティクス，インコーポレイテッド
Publication of JP2024537839A publication Critical patent/JP2024537839A/ja
Publication of JP2024537839A5 publication Critical patent/JP2024537839A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024519989A 2021-10-15 2022-10-14 アキシチニブのプロドラッグ Pending JP2024537839A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163255998P 2021-10-15 2021-10-15
US63/255,998 2021-10-15
PCT/US2022/046750 WO2023064578A1 (en) 2021-10-15 2022-10-14 Prodrugs of axitinib

Publications (2)

Publication Number Publication Date
JP2024537839A true JP2024537839A (ja) 2024-10-16
JP2024537839A5 JP2024537839A5 (enExample) 2025-10-06

Family

ID=85987895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519989A Pending JP2024537839A (ja) 2021-10-15 2022-10-14 アキシチニブのプロドラッグ

Country Status (8)

Country Link
US (1) US20250092013A1 (enExample)
EP (1) EP4416132A4 (enExample)
JP (1) JP2024537839A (enExample)
CN (1) CN118119599A (enExample)
AU (1) AU2022362310A1 (enExample)
CA (1) CA3232086A1 (enExample)
MX (1) MX2024003968A (enExample)
WO (1) WO2023064578A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081410A1 (en) * 2022-10-14 2024-04-18 Ocular Therapeutix, Inc. Prodrugs, formulations and methods thereof
AU2024251447A1 (en) 2023-04-11 2025-08-21 Ocular Therapeutix, Inc. Ocular implant comprising axitinib polymorph iv

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
US20210078970A1 (en) * 2019-08-30 2021-03-18 Risen (Suzhou) Pharma Tech Co., Ltd. Prodrugs of the tyrosine kinase inhibitor for treating cancer
WO2021035360A1 (en) * 2019-08-30 2021-03-04 Risen (Suzhou) Pharma Tech Co., Ltd. Prodrugs of the tyrosine kinase inhibitor for treating cancer
CN112442010B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 一类前药化合物及其在治疗癌症方面的应用

Also Published As

Publication number Publication date
US20250092013A1 (en) 2025-03-20
EP4416132A1 (en) 2024-08-21
WO2023064578A1 (en) 2023-04-20
CN118119599A (zh) 2024-05-31
MX2024003968A (es) 2024-04-29
EP4416132A4 (en) 2025-09-03
AU2022362310A1 (en) 2024-04-11
CA3232086A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
KR102520771B1 (ko) 전안방내 약물 전달 데포
JP2021046429A (ja) ハイドロゲル薬物送達インプラント
MXPA03008498A (es) Procesamiento en dos fases de polimeros termosensibles para uso como biomateriales.
CN120000836A (zh) 树状体-生物粘合剂聚合物水凝胶纳米胶水和其用途
US20250092013A1 (en) Prodrugs of axitinib
US20180008718A1 (en) Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
WO2017015616A1 (en) Ocular protein delivery
JP2024544025A (ja) 押し出しされる眼内挿入物またはインプラント及びその製造方法
JP2025534605A (ja) プロドラッグ、製剤、及びそれらの方法
US12453724B2 (en) Ocular implant containing a tyrosine kinase inhibitor
EP2042538A1 (en) Amphiphilic copolymers and compositions containing such polymers
AU2024251578A1 (en) Bio-orthogonal hydrogels for sustained release drug delivery
JP2025526731A (ja) 持続的薬物送達のためのオルガノゲル、その調製及び使用の方法
WO2026107180A1 (en) Implant injector device
KR20250160197A (ko) 폴리(에틸렌 글리콜) 기반 덴드리머-유사 초분지형 거대분자, 이의 제조 방법 및 용도
CN118591369A (zh) 挤出式眼部插入物或植入物及其方法
HK40115702A (zh) 原位形成的具有共价键的单一溶液水凝胶、组成设计和使用该水凝胶的医疗程序
CN118742291A (zh) 包含非甾体抗炎剂的小管内插入物
HK1252836B (en) Drug delivery from hydrogels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250926